Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model
出版年份 2022 全文链接
标题
Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model
作者
关键词
-
出版物
NEUROPHARMACOLOGY
Volume 218, Issue -, Pages 109213
出版商
Elsevier BV
发表日期
2022-08-12
DOI
10.1016/j.neuropharm.2022.109213
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neurodegeneration and neuroinflammation are linked, but independent of alpha‐synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease
- (2022) Pierre Garcia et al. GLIA
- Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson’s disease
- (2021) Md. Ezazul Haque et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A
- (2021) T. Eteläinen et al. FREE RADICAL BIOLOGY AND MEDICINE
- CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
- (2021) Alan J. Fowler et al. Neurology-Genetics
- Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy
- (2021) H. Cui et al. BIOCHEMICAL PHARMACOLOGY
- iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates
- (2020) A. H. Laperle et al. NATURE MEDICINE
- Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
- (2020) Rob M A de Bie et al. LANCET NEUROLOGY
- Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
- (2020) Mónica Gómez-Benito et al. Frontiers in Pharmacology
- New tricks of prolyl oligopeptidase inhibitors – A common drug therapy for several neurodegenerative diseases
- (2019) Reinis Svarcbahs et al. BIOCHEMICAL PHARMACOLOGY
- Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes
- (2019) Sarah H. Shahmoradian et al. NATURE NEUROSCIENCE
- Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors
- (2019) Tommi P. Kilpeläinen et al. ACS Medicinal Chemistry Letters
- Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease
- (2019) Tommi Kilpeläinen et al. Scientific Reports
- Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A
- (2019) Reinis Svarcbahs et al. PHARMACOLOGICAL RESEARCH
- The concept of alpha-synuclein as a prion-like protein: ten years after
- (2018) Jennifer A. Steiner et al. CELL AND TISSUE RESEARCH
- ELISA method to detect α-synuclein oligomers in cell and animal models
- (2018) Louise Berkhoudt Lassen et al. PLoS One
- Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
- (2018) Reinis Svarcbahs et al. Scientific Reports
- Implementation of deep neural networks to count dopamine neurons in substantia nigra
- (2018) Anna-Maija Penttinen et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- A53T mutant alpha-synuclein induces tau dependent postsynaptic impairment independent of neurodegenerative changes
- (2018) Peter J. Teravskis et al. JOURNAL OF NEUROSCIENCE
- Regulation of selective autophagy: the p62/SQSTM1 paradigm
- (2017) Trond Lamark et al. Essays in Biochemistry
- Overexpression of α-synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis
- (2017) Adolfo Garcia Erustes et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture
- (2017) Timo T. Myöhänen et al. NEUROSCIENCE LETTERS
- Protein aggregation into insoluble deposits protects from oxidative stress
- (2017) Anita Carija et al. Redox Biology
- AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
- (2017) Chi Wang Ip et al. Acta Neuropathologica Communications
- Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
- (2017) Antonio Martin-Bastida et al. Scientific Reports
- An update on the diagnosis and treatment of Parkinson disease
- (2016) Philippe Rizek et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector–Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain
- (2016) Reinis Svarcbahs et al. JOURNAL OF NEUROSCIENCE
- Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse
- (2016) Ulrika H Julku et al. MOLECULAR NEUROBIOLOGY
- Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease
- (2016) Kuo-Hsuan Chang et al. PARKINSONISM & RELATED DISORDERS
- Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease
- (2016) Tianfang Jiang et al. PROGRESS IN NEUROBIOLOGY
- Prolyl Oligopeptidase Enhances α-Synuclein Dimerization via Direct Protein-Protein Interaction
- (2015) Mari H. Savolainen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies
- (2015) Anna Villar-Piqué et al. JOURNAL OF NEUROCHEMISTRY
- The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
- (2014) Mari H. Savolainen et al. NEUROBIOLOGY OF DISEASE
- Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers
- (2014) Lana Dokleja et al. NEUROSCIENCE LETTERS
- A Generic Method for Design of Oligomer-Specific Antibodies
- (2014) Kristoffer Brännström et al. PLoS One
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome
- (2013) Suzanne Lesage et al. ANNALS OF NEUROLOGY
- KYP-2047 Penetrates Mouse Brain and Effectively Inhibits Mouse Prolyl Oligopeptidase
- (2013) Aaro J. Jalkanen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases
- (2013) Mohamed E. Shaker et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models
- (2013) M. L. Hebron et al. HUMAN MOLECULAR GENETICS
- The Clathrin-Dependent Localization of Dopamine Transporter to Surface Membranes Is Affected by α-Synuclein
- (2013) Haya Kisos et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases
- (2013) M.J. Hannula et al. NEUROSCIENCE
- Flotillins Regulate Membrane Mobility of the Dopamine Transporter but Are Not Required for Its Protein Kinase C Dependent Endocytosis
- (2013) Tatiana Sorkina et al. TRAFFIC
- A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
- (2012) TT Myöhänen et al. BRITISH JOURNAL OF PHARMACOLOGY
- Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship
- (2012) Maria Xilouri et al. MOLECULAR NEUROBIOLOGY
- Brain Pharmacokinetics of Two Prolyl Oligopeptidase Inhibitors, JTP-4819 and KYP-2047, in the Rat
- (2011) Aaro J. Jalkanen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
- (2011) James B. Koprich et al. PLoS One
- Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease
- (2011) Arianna Bellucci et al. PLoS One
- Serine 129 Phosphorylation Reduces the Ability of α-Synuclein to Regulate Tyrosine Hydroxylase and Protein Phosphatase 2Ain Vitroandin Vivo
- (2010) Haiyan Lou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
- (2010) Ashley R. Winslow et al. JOURNAL OF CELL BIOLOGY
- Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
- (2010) James B Koprich et al. Molecular Neurodegeneration
- -Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
- (2010) J. Burre et al. SCIENCE
- α-Synuclein and dopamine at the crossroads of Parkinson's disease
- (2010) Lara Lourenço Venda et al. TRENDS IN NEUROSCIENCES
- Protein Misfolding and Aggregation in Parkinson's Disease
- (2009) Jeanne M.M. Tan et al. ANTIOXIDANTS & REDOX SIGNALING
- Genome-wide association study reveals genetic risk underlying Parkinson's disease
- (2009) Javier Simón-Sánchez et al. NATURE GENETICS
- α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice
- (2008) Tshianda N.M. Alerte et al. NEUROSCIENCE LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started